COSMIC-313: Phase III Study of Nivolumab + Ipilimumab ± Cabozantinib in Previously Untreated IMDC Intermediate- or Poor-Risk Advanced RCC

September 9-13, 2022; Paris, France
Results from the phase III COSMIC-313 study showed that PFS was significantly improved with the addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC.
Format: Microsoft PowerPoint (.ppt)
File Size: 229 KB
Released: September 22, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Exelixis, Inc.
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.

Related Content

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: November 14, 2022 Expired: November 13, 2023

Download these expert-selected slides on treatments for early and later-stage renal cell carcinoma.

Katy Beckermann, MD, PhD Naomi B. Haas, MD Eric Jonasch, MD Elizabeth R. Plimack, MD, MS Released: October 21, 2022

Downloadable clinical resource with practical guidance on preventative care plans for transgender patients, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: October 7, 2022

Download this expert slideset on strategies for developing compassionate care plans with transgender patients based on their current anatomy

person default Lauren Radziejewski, DNP Released: October 4, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings